PITTSBURGH – January 31, 2017 – Noveome Biotherapeutics, Inc., a clinical-stage company and leader in the field of paracrine signaling, today announced the publication of groundbreaking preclinical data in a multiple sclerosis (MS) model with ST266, the company’s novel secretome. Intranasally delivered ST266 demonstrated anti-inflammatory activity and prevented retinal ganglion cell (RGC) loss in the optic nerve, showing its therapeutic potential for treating optic neuritis, the most common presenting sign of MS. The research was conducted in the laboratory of Kenneth S. Shindler, M.D., Ph.D., a professor of Ophthalmology in the Perelman School of Medicine at the University of Pennsylvania, with funding support provided by Noveome, and was published today in Nature Scientific Reports in an article titled, “Intranasal Delivery of a Novel Amnion Cell Secretome Prevents Neuronal Damage and Preserves Function in a Mouse Multiple Sclerosis Model.”
—Second Disease Indication Shows Versatility of Paracrine Signaling Solution—
PITTSBURGH – December 5, 2016 – Noveome Biotherapeutics, Inc., a clinical-stage company and leader in the field of paracrine signaling, today announced the initiation of a Phase 2 clinical trial of ST266, the company’s novel secretome, to treat patients with allergic conjunctivitis, an ocular inflammation condition caused by exposure to an allergen. ST266, the company’s lead product, harnesses the power of paracrine signaling and has been found to help promote cellular homeostasis, modulate inflammation and regenerate damaged cells. Paracrine signaling is the dynamic communication between nearby cells to induce a coordinated change in cell behavior.
When a group of high schools students walked into Noveome Biotherapeutics, Inc.’s offices and labs recently, many of them were wondering whether they might be looking at their own future. “This is a chance to experience things in case we truly want to go into that field,” said Noah, a senior at Cardinal Wuerl North Catholic High School. He was among the 15 students – 3 boys and 12 girls – who visited Noveome as part of an Advanced Placement Biology STEM career tour. A majority of these students said they were interested in pursuing college degrees in the sciences.
— Company is committed to fully explore the potential of ST266 across several disease areas and multiple indications —
PITTSBURGH – June 15, 2016 – Noveome Biotherapeutics, Inc., a clinical-stage company focused on the biology of paracrine signaling, today announced the initiation of a phase 2 clinical trial of its novel secretome, ST266, to treat patients with moderate to severe periodontitis, a severe inflammatory condition that leads to damage of the soft tissue and destruction of the bone that supports the tooth. The company is the leading innovator in paracrine signaling for the clinical development of novel biotherapeutic products that work safely and effectively in complex biologic processes.
— Company emerges with a new name and preparations under way for later stage clinical development of their lead product ST266 —
PITTSBURGH – April 13, 2016 – Noveome Biotherapeutics, Inc., a clinical-stage company focused on the biology of paracrine signaling, today announced that the company, formerly known as Stemnion, Inc., has emerged with a new focus and top-line results from their lead product, ST266, in three Phase 1 clinical trials.